Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 20, 2011 - Issue 8
Submit an article Journal homepage
281
Views
8
CrossRef citations to date
0
Altmetric
Original Research

An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels

Zheng WangFudan University, Liver Cancer Institute and Zhongshan Hospital, 136 Yi Xue Yuan Road, 200032 Shanghai, P.R. China+86 21 64037181; +86 21 64037181; [email protected]
,
Jie HuFudan University, Liver Cancer Institute and Zhongshan Hospital, 136 Yi Xue Yuan Road, 200032 Shanghai, P.R. China+86 21 64037181; +86 21 64037181; [email protected]
,
Shuang-Jian QiuFudan University, Liver Cancer Institute and Zhongshan Hospital, 136 Yi Xue Yuan Road, 200032 Shanghai, P.R. China+86 21 64037181; +86 21 64037181; [email protected]
,
Xiao-Wu HuangFudan University, Liver Cancer Institute and Zhongshan Hospital, 136 Yi Xue Yuan Road, 200032 Shanghai, P.R. China+86 21 64037181; +86 21 64037181; [email protected]
,
Zhi DaiFudan University, Liver Cancer Institute and Zhongshan Hospital, 136 Yi Xue Yuan Road, 200032 Shanghai, P.R. China+86 21 64037181; +86 21 64037181; [email protected]
,
Chang-Jun TanFudan University, Liver Cancer Institute and Zhongshan Hospital, 136 Yi Xue Yuan Road, 200032 Shanghai, P.R. China+86 21 64037181; +86 21 64037181; [email protected]
,
Jian ZhouFudan University, Liver Cancer Institute and Zhongshan Hospital, 136 Yi Xue Yuan Road, 200032 Shanghai, P.R. China+86 21 64037181; +86 21 64037181; [email protected]
&
Jia FanFudan University, Liver Cancer Institute and Zhongshan Hospital, 136 Yi Xue Yuan Road, 200032 Shanghai, P.R. China+86 21 64037181; +86 21 64037181; [email protected]
, MD PHD show all
Pages 1039-1045 | Published online: 14 Jun 2011

Bibliography

  • El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007;37:S88-94
  • Kudo M. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology 2008;20:S1-12
  • Tang ZY, Yu YQ, Zhou XD, Progress and prospects in hepatocellular carcinoma surgery. Ann Chir 1998;52:558-63
  • Addeo R, Caraglia M, Del Prete S. Highlights of regional meeting of Italian Southern Oncological Group (GOIM): focus on hepatocellular carcinoma: biological and clinical background, therapeutic guide-lines and perspectives. 7 November 2008, Naples, Italy. Expert Opin Investig Drugs 2009;18(3):373-8
  • Ercolani G, Grazi GL, Ravaioli M, Liver resection for hepatocellular carcinoma on cirrhosis. Ann Surg 2003;237:536-43
  • Regimbeau JM, Abdalla EK, Vauthey JN, Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study. J Surg Oncol 2004;85:36-41
  • Kohno H, Nagasue H, Hayashi T, Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC). Hepatogastroenterology 1996;43:1405-9
  • Lai EC, Lo CM, Fan ST, Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma. Arch Surg 1998;133:183-8
  • Lin SM, Lin CJ, Hsu CW. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2003;100:376-82
  • Mazzaferro V, Romito R, Schiavo M, Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006;44:1543-54
  • Lau WY, Leung TW, Ho SK, Adjuvant intra-arterial iodine-131-labelled lipiodol for respectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999;353:797-801
  • Yamamoto M, Arii S, Sughara K, Adjuvant oral chemotherapy after curative resection of hepatocellular carcinoma. Br J Surg 1996;83:336-40
  • Ono T, Nagasue N, Kohno H, Adjuvant chemotherapy with epirubicin and carmfur after radical resection of hepatocellular carcinoma: a prospective randomized study. Semin Oncol 1997;24:S6-18
  • Takayama T, Sekine T, Makuuchi M, Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet 2000;356:802-7
  • Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48:S20-37
  • Worns MA, Galle PR. Novel inhibitors in development for hepatocellular carcinoma. Expert Opin Investig Drugs 2010;19:615-29
  • Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
  • Zhang Z, Zhou X, Shen H, Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med 2009;7:41
  • Chang YS, Adnane J, Trail PA, Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007;59:561-74
  • Huynh H, Nguyen TT, Chow KH, Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 2003;3:19
  • Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-310
  • Wilhelm SM, Carter C, Tang L, BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
  • Wilhelm SM, Adnane L, Newell P, Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-40
  • Zhang W, Konopleva M, Ruvolo VR, Sorafenib induces apoptosis of AML cells via Bimmediated activation of the intrinsic apoptotic pathway. Leukemia 2008;22:808-18
  • Abou-Alfa GK, Schwartz L, Ricci S, Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300
  • Feng YX, Wang T, Deng YZ, Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology 2011;53:483-92
  • Kim R, El-Gazzaz G, Tan A, Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology 2010;79:62-6

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.